Why FAP Has Become a Priority Target in Solid Tumor Theranostics

Fibroblast activation protein (FAP) is a type II transmembrane serine protease that is overexpressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment of a wide range of solid tumors, while remaining largely absent from normal adult tissue. This differential expression pattern makes FAP one of the most selective stroma-level targets available for theranostic development — offering the prospect of imaging and treating the same patient with matched diagnostic and therapeutic radiopharmaceuticals.

FAP-expressing CAFs promote tumor growth, immune evasion, and metastasis — roles documented extensively in the peer-reviewed literature, including reviews published in Nature-family journals. The therapeutic rationale is therefore dual: destroying FAP-expressing stromal cells can simultaneously deliver cytotoxic radiation to the tumor microenvironment and disrupt the pro-tumorigenic stroma that shields cancer cells from immune attack.

The clinical proof-of-concept for FAP targeting was accelerated by the success of small molecule fibroblast activation protein inhibitor (FAPI) radiotracers. A prospective cohort study evaluating FAPI-based PET-CT in over 80 different tumor types demonstrated superior tumor-to-background ratios compared to FDG-PET in many cancers including pancreatic cancer, breast cancer, hepatocellular carcinoma, and gastric cancer. This large-scale clinical evidence base has validated FAP as an imaging target and created the foundation for the next generation of FAP-targeted agents: radiolabeled antibodies.

The Radionuclide Toolkit: Diagnostic and Therapeutic Isotopes in FAP Antibody Programs

FAP-targeted radiolabeled antibody programs use distinct radionuclides for imaging versus therapy, with the choice of isotope dictating the clinical application, dosimetry, and manufacturing requirements. The radionuclide landscape for anti-FAP antibodies spans at least seven isotopes across both modalities.

For diagnostic immunoPET imaging, ⁸⁹Zr and ⁶⁴Cu are the most widely studied isotopes. A preclinical study of a ⁸⁹Zr-labeled anti-FAP antibody — using deferoxamine (DFO) chelation — demonstrated specific uptake in FAP-expressing xenograft tumors with high tumor-to-background ratios in biodistribution and PET imaging studies, supporting its potential as a diagnostic imaging agent. The longer half-life of ⁸⁹Zr (78.4 hours) is well matched to the slow pharmacokinetics of full IgG antibodies. ⁶⁸Ga has also been explored for SPECT/PET applications with FAP-targeting molecules, as covered in Novartis AG’s patent portfolio.

On the therapeutic side, ¹⁷⁷Lu is the most clinically advanced isotope for FAP-targeted radioimmunotherapy. Preclinical and early clinical evaluation of a ¹⁷⁷Lu-labeled anti-FAP antibody demonstrated specific uptake in FAP-expressing tumors, tumor growth inhibition in xenograft models, and acceptable safety profiles in patients with advanced solid tumors. Alpha-emitting isotopes ²²⁵Ac and ²¹³Bi — as well as lead-212 (²¹²Pb) — are also covered in key patent filings, reflecting interest in higher-LET (linear energy transfer) radiotherapy for FAP-positive tumors. Memorial Sloan Kettering Cancer Center’s patent program explicitly covers ²¹¹At as well, extending the alpha-emitter toolkit.

“FAP-targeted antibodies offer the potential for longer tumor retention due to their large molecular size — a pharmacokinetic advantage that may translate into superior therapeutic efficacy compared to small molecule FAPI inhibitors.”

Company-by-Company: Who Is Building the FAP-Targeted Radiolabeled Antibody Pipeline

The FAP-targeted radiolabeled antibody landscape is unusually diverse, with academic medical centers, large pharmaceutical companies, and specialist oncology biotechs each staking out distinct intellectual property positions. Patent analysis via PatSnap reveals at least five major organizational clusters with active programs.

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) holds one of the most comprehensive radiolabeled anti-FAP antibody patents in the field, covering antibodies labeled with ⁸⁹Zr, ⁶⁴Cu, ¹⁷⁷Lu, ²²⁵Ac, ²¹²Pb, ²¹³Bi, and ²¹¹At for use in PET imaging, SPECT imaging, and radionuclide therapy. The MSKCC program, involving inventors including Wolfgang Alfred Weber and Jason Scott Lewis, represents a broad theranostic platform rather than a single agent, positioning the institution as a key licensor or partner for commercial development.

Novartis AG

Novartis AG has filed patents for FAP-directed radiopharmaceuticals covering both small molecules and macromolecules — including antibodies, antibody fragments, polypeptides, and peptides — labeled with chelate moieties or radiohalogens for PET imaging, SPECT imaging, radiotherapy, and boron neutron capture therapy. The Novartis approach explicitly encompasses bimodal and theranostic imaging agents, reflecting the company’s established expertise in radioligand therapy following its acquisition of Advanced Accelerator Applications.

Bayer AG

Bayer AG’s anti-FAP antibody patent covers antibodies with specified CDR sequences that bind selectively to FAP, with applications in both the treatment and diagnosis of FAP-related diseases including cancer. The Bayer program is positioned for both therapeutic and diagnostic use, with the patent covering pharmaceutical compositions and related methods.

Philogen S.p.A

Philogen S.p.A, the Italian clinical-stage biotech, has built a substantial FAP-targeting portfolio around its F19 antibody (anti-FAP) and L19 antibody (anti-fibronectin EDB). Philogen’s programs include antibody-cytokine fusion proteins (immunocytokines) and antibody-drug conjugates (ADCs) targeting FAP, with cytokine components including IL-2, IL-12, IL-15, TNF, interferon-alpha, and interferon-gamma. The F19 antibody — historically known as sibrotuzumab — is one of the earliest and most cited anti-FAP antibodies in the scientific literature, providing Philogen with a strong prior art position.

University of Zurich

The University of Zurich holds a patent on anti-FAP antibodies and conjugates thereof, covering conjugation with drugs, labels, and radionuclides for ADCC, ADCP, CDC, oncological, and imaging purposes. The Zurich program, involving inventor Roger Schibli — a leading figure in radiopharmaceutical chemistry — provides a strong academic foundation for translational development.

Antibody Format Choices and Their Theranostic Trade-offs

Not all anti-FAP antibody programs use full IgG molecules — the choice of antibody format has significant implications for pharmacokinetics, tumor-to-background contrast, manufacturing, and the optimal radionuclide pairing. The comparative analysis of antibody formats for FAP-targeted theranostics covers five distinct structural classes: full IgG antibodies, Fab fragments, minibodies, diabodies, and nanobodies.

Full IgG antibodies offer longer serum half-life and higher binding avidity, but their slow clearance from blood means tumor-to-background contrast develops more slowly — typically requiring imaging several days post-injection when using long-lived isotopes such as ⁸⁹Zr. This slower pharmacokinetic profile is, however, well suited to therapeutic radioimmunotherapy applications where sustained tumor exposure is desirable. The ¹⁷⁷Lu-labeled anti-FAP full IgG antibody evaluated in early clinical studies demonstrated this principle, showing tumor uptake in patients with advanced solid tumors at acceptable safety profiles.

Antibody fragments, including Fab fragments and minibodies, offer faster pharmacokinetics and more rapid tumor-to-background contrast, but shorter tumor retention — a trade-off that makes them attractive for immunoPET imaging but potentially less effective for radioimmunotherapy where dwell time drives efficacy. Nanobodies represent an emerging format with very rapid clearance and small size, enabling high-contrast imaging within hours, but their short tumor retention limits their therapeutic utility without engineering modifications.

The broader field of radiolabeled antibodies — as reviewed in the scientific literature and tracked by organisations such as WIPO through its annual Global Innovation Index — uses diagnostic radionuclides including ⁸⁹Zr, ⁶⁴Cu, ¹²⁴I, and ⁶⁸Ga, and therapeutic radionuclides including ¹⁷⁷Lu, ²²⁵Ac, ²¹³Bi, ¹³¹I, and ⁹⁰Y. The FAP-targeted antibody programs reviewed here cover most of this isotope spectrum, indicating that the field is pursuing a comprehensive theranostic toolkit rather than converging on a single agent.

From Bench to Bedside: Clinical Translation and the Road Ahead

Clinical translation of FAP-targeted radiolabeled antibodies is at an early but accelerating stage, with preclinical validation in multiple xenograft models now being followed by first-in-human studies. The trajectory mirrors — though lags — the clinical path of PSMA-targeted radioligand therapy, which culminated in the FDA approval of lutetium-177-PSMA-617 in 2022 for metastatic castration-resistant prostate cancer, as documented in peer-reviewed literature and tracked by regulatory bodies including the FDA.

Early clinical evaluation of ¹⁷⁷Lu-labeled anti-FAP antibodies in patients with advanced solid tumors has demonstrated acceptable safety profiles and evidence of tumor uptake, supporting the feasibility of FAP-targeted radioimmunotherapy. These early results provide the clinical validation needed to advance larger, dose-escalation and efficacy studies. Separately, the preclinical evaluation of ⁸⁹Zr-labeled anti-FAP antibodies has shown specific tumor uptake with high tumor-to-background ratios in xenograft models, establishing the imaging arm of the theranostic pair.

The broader context for FAP-targeted theranostics is shaped by the established success of FAPI-based PET-CT. Prospective clinical data in over 80 tumor types has demonstrated that FAPI-PET offers superior tumor-to-background ratios compared to FDG-PET in many cancers — a finding that validates FAP as a clinically actionable target and creates a patient identification pathway for subsequent antibody-based therapy. Regulatory and scientific bodies including the EANM (European Association of Nuclear Medicine) have published guidelines and position papers on theranostic radiopharmaceuticals that are shaping the clinical development frameworks for FAP-targeted agents.

Several strategic challenges remain. FAP expression is heterogeneous across and within tumors, raising questions about patient selection and the risk of acquired resistance through downregulation of stromal FAP. The short tumor residence time of current small molecule FAPI compounds — a limitation explicitly noted in the literature — is one reason why FAP-targeted antibodies are attracting increasing interest: their larger molecular size confers longer tumor retention, potentially addressing the residence time problem. Bispecific antibody approaches — targeting FAP alongside immune checkpoint molecules such as PD-L1 or CTLA-4, and potentially labeled with radionuclides such as ⁸⁹Zr or ⁶⁴Cu for theranostic imaging — represent a further evolution of the field, as covered by Boehringer Ingelheim International’s patent on bispecific antibodies against FAP and DR5.

“FAPI-based PET-CT in over 80 different tumor types demonstrates superior tumor-to-background ratios compared to FDG-PET in many cancers including pancreatic cancer, breast cancer, hepatocellular carcinoma, and gastric cancer — validating FAP as a clinically actionable theranostic target.”

The patent landscape analysis conducted via PatSnap’s innovation intelligence platform reveals that the FAP-targeted radiolabeled antibody field is now sufficiently mature to attract both academic and large-pharma investment, with IP filings spanning multiple continents and legal systems. Organizations seeking to enter or monitor this space can use PatSnap Eureka’s drug intelligence capabilities to track pipeline evolution, freedom-to-operate, and competitive positioning across all active programs.